Key characteristics of development candidate TRIN 2755. TRIN 2755 --is based on a new chemistry with substance patent applied for --exerts selective anti-tumour activity in distinct xenograft tumours --induces dose-dependent tumour remission in animal models --achieves complete remission of tumours as evidenced by inhibition --of tumour regrowth in the longterm